The first subject expected to be dosed by year-end
Company announces OTX-TKI trade name AXPAXLI
https://www.globenewswire.com/news-release/2023/11/01/2771115/0/en/Ocular-Therapeutix-Receives-FDA-Agreement-Under-Special-Protocol-Assessment-SPA-for-its-First-Pivotal-Clinical-Trial-of-OTX-TKI-in-Wet-AMD.html
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.